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Follicular lymphoma (FL), commonly referred to
as an indolent lymphoma, is the second most common
type of non-Hodgkin lymphoma (NHL). FL has an in-
cidence of 15,000 new cases/year in the United
States, and the median age is 60 years old at diagnosis
[1]. Median survival rates have historically reported to
be in the range of 8 to 10 years. Although the availabil-
ity of newer agents, including the monoclonal
antibody rituximab, has dramatically improved out-
come and survival, FL remains incurable with standard
therapy [2]. Moreover, clinical behavior is markedly
heterogeneous with some patients developing progres-
sive or transformed disease early and 15% dying within
2 years from diagnosis, whereas others remain alive for
decades without need for treatment. With more avail-
able treatment options, including novel agents and
hematopoietic cell transplantation (HCT), improved
prognostication and identification of predictive
markers of response are necessary to facilitate individ-
ualized risk-adapted therapy.
The hallmark genetic abnormality associated with
FL is the presence of a chromosomal translocation,
t(14;18)(q32;q21) or variant in 85% of the cases, which
juxtaposes the immunoglobulin heavy chain gene on
chromosome 14 with the BCL2 oncogene on chromo-
some 18 leading to constitutive expression of the BCL2
protein. Although critical for lymphomagenesis, this
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to apoptosis, thus allowing the cells a survival advan-
tage and facilitating the acquisition and retention of
secondary genetic abnormalities that likely determines
the clinical phenotype. Whereas the underlying biol-
ogy of the malignant cell is a key component contrib-
uting to clinical behavior, it has become increasingly
recognized that outcome in FL is influenced by a com-
plex interplay between the malignant cell, immune
cells of the microenvironment, and host constitutional
genetics (Figure 1) [3].Clinical Prognostic Factors
The International Prognostic Index (IPI) devel-
oped for aggressive lymphoma also reliably identifies
risk groups in FL, however, it only classifies a small
proportion of patients into the highest-risk category
and, therefore, has limited utility [4,5]. In 2004, the
Follicular Lymphoma International Prognostic Index
(FLIPI) was published resulting from a multicenter
effort [6]. It includes five adverse parameters: age
.60 years, stage III to IV, hemoglobin \120 g/L,
number of involved nodal areas .4, and elevated se-
rum lactate dehydrogenase, and classifies patients
into three groups with 10-year overall survival (OS)
rates of 71%, 51%, and 36%, respectively. The FLIPI
was subsequently shown to be predictive in patients
treated with immunochemotherapy, patients in first
relapse, and to correlate with the risk of transformation
[7-9].More recently, the FLIPI-2 index was published,
incorporating ß2-microglobulin, lymph node size
.6 cm, bone marrow involvement, anemia, and age
over 60 years [10]. The majority of patients in the
FLIPI-2 study cohort had received immunochemo-
therapy, and the 3-year progression-free survival
(PFS) rates ranged from 51% to 91% (Table 1). The
FLIPI and FLIPI-2 indices are useful in clinical prac-
tice and valuable for stratification in clinical trials.
However, they remain a clinical surrogate for biologic
heterogeneity, and marked variations in outcome re-
main within each risk group. In addition, they have
limited ability to identify a subgroup of patients with
Figure 1. Factors influencing outcome in follicular lymphoma.
Table 1. Clinical Prognostic Indices in Follicular Lymphoma
FLIPI [6]a (n 5 1,795, patients not treated with rituximab)
Risk group No. of Factors % Patients 5-yr OS (%) 10-yr OS (%)
Low 0-1 36 91 71
Intermediate 2 37 78 51
High $3 27 53 36
FLIPI-2 [10]b (n 5 832, 68% treated with rituximab)
Risk group No. of Factors % Patients 3-yr PFS (%) 5-yr PFS (%)
Low 0 20 91 80
Intermediate 1-2 53 69 51
High $3 27 51 19
FLIPI indicates Follicular Lymphoma International Prognostic Index; OS,
overall survival; PFS, progression-free survival.
aAdverse risk factors: age >60 yr, stage III/IV, hemoglobin <120 g/L,
elevated serum lactate dehydrogenase, number of nodal sites >4.
bAdverse risk factors: age >60 yr, hemoglobin <120 g/L, elevated
ß2-microglobulin, bone marrow involvement, nodal size >6 cm.
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or alternative treatment approaches.
Histologic Grade
Three grades of FL are recognized by the World
Health Organization based on the proportion of cen-
troblasts seen in neoplastic follicles. Grade 3 has
been further subclassified into grade 3a with centro-
cytes present, and grade 3b contains solid sheets of
centroblasts. The correlation of clinical grade to clin-
ical outcome is an unresolved debate. There is general
consensus that patients with FL grades 1 and 2 behave
indolently, and these entities have been merged in the
recent edition of theWorld Health Organization [11].
FL grade 3 seems to behave more aggressively, but re-
ports have been conflicting regarding its potential cur-
ability with anthracycline-based therapy [12,13]. It has
been suggested that FL grade 3a forms part of
a spectrum of indolent lymphoma with grades 1 and
2, and grade 3b may be similar to diffuse large B-cell
lymphoma (DLBCL), but several reports have found
no difference in outcome between FL grades 3a and
3b when treated with anthracycline-based therapy
[12-14]. Grade 3 FL has historically been treated
similarly to DLBCL, and any area of DLBCL within
a follicular lymphoma should be diagnosed and
treated like a DLBCL, according to the National
Comprehensive Center Network guidelines.
Molecular Prognostic Factors
Cytogenetics
In addition to the t(14,18) translocation, themajority
of patients with FL harbor additional karyotypic
abnormalities at diagnosis. The mean number of alter-
ations is highly variable, with higher numbers of alter-
ations tending to correlate with a higher grade of FL.Recurring secondary cytogenetic events include gains
of chromosome 1q, 2p, 6p, 7, 8, 12q, 18, X, and
der18q, and losses of 1p, 6q, 10q, 13q, and 17p [15-19].
The genetic alterations most strongly associated with
a poor prognosis have also been correlated with
a higher risk of transformation and include deletions of
1p, 6q, and 17p, and gains of 7 and 12q [20]. In contrast,
some studies have failed to showa link between these sec-
ondary cytogenetic changes and outcome [21]. Translo-
cations involvingBCL6occur infrequently inFLgrades 1
and 2 but were noted in 18% of cases of FL grade 3a and
44% of FL grade 3b and have been shown to correlate
with a risk of transformation [22].
Gene-expression profiling
Various studies have used gene expression profil-
ing (GEP) to elucidate prognostic variables in FL,
which highlights the major role of immune cells in
S84 Biol Blood Marrow Transplant 18:S82-S91, 2012L. H. Sehn et al.determining outcome [23-26]. A landmark study of
GEP was performed by the Leukemia Lymphoma
Molecular Profiling Project using whole biopsy
specimens from 191 patients with untreated FL [24].
Two signatures of gene expression were identified
that best correlated with survival prediction. The
‘‘immune-response 1’’ signature included genes en-
coding for T cell markers and genes that are highly ex-
pressed in macrophages and predicted a favorable
outcome. The ‘‘immune-response 2’’ signature in-
cluded genes that are preferentially expressed in mac-
rophages, dendritic cells, or both, and predicted an
unfavorable outcome. When patients were grouped
into quartiles based on their survival-predictor scores,
which reflected the signature expression levels within
their biopsies, median survival ranged from 3.9 years
to 13.6 years. The predictive capacity of the gene ex-
pression model was independent of the IPI and, inter-
estingly, the gene expression signatures reflected the
biologic characteristics of the nonmalignant cells
within the tumor. Given the complexities of this tech-
nique, lack of validated commercially available plat-
forms, and the requirement for fresh tissue, GEP is
not yet ready for routine clinical use.
Microenvironment
Follicular lymphoma cells reside within a microen-
vironment that closely resembles the normal germinal
center and are intimately associatedwith follicular den-
dritic cells, T cells, histiocytes, and macrophages. It is
believed that interactions between these cells modulate
the growth and survival of FL cells, as was suggested by
GEP studies [23-25,27]. Immunohistochemistry
(IHC) studies have explored the correlation between
nonneoplastic cells and outcome. Conflicting results
have emerged, likely due to small study cohorts, vari-
able treatments received, and poor reproducibility of
IHC methodology [28].
Tumor-associated macrophages have been evalu-
ated using IHC for CD68. Increased macrophage
content has been associated with inferior survival inde-
pendent of the IPI in patients treated with chemother-
apy [29]. In more recent trials, the negative impact of
high macrophage content was no longer evident in pa-
tients receiving immunochemotherapy.Various subsets
of T cells within the nonneoplastic cells in FL biopsies
have also been found to affect prognosis. Such subsets
include helper CD41 T cells, cytotoxic CD81 T cells,
and immunosuppressive T-regulatory cells (CD41,
CD251, and FOXP31), but the exact role exerted by
these subsets is not completely understood.
Host Constitutional Genetics
In view of the prominent role played by host im-
mune cells, the potential for host genetic factors to
predict FL treatment response and prognosis has
been explored [30]. Single nucleotide polymorphisms(SNPs) are changes in the DNA sequence by 1 base
pair. SNPs in the FcgR genes may significantly alter
the binding affinity between the Fc portion of rituxi-
mab and the Fc receptors on macrophages. Several
studies have reported a correlation between the
FcRIIIA genotype and outcome after single-agent rit-
uximab in patients with FL [31,32]. Patients
homozygous for 158VV FcRIIIA polymorphism did
significantly better than the heterozygotes, 158VF. A
study of patients with recurrent FL confirmed these
findings and identified a second polymorphic site
related to the duration of response (FcRIIA 131
histidine/arginine) [33]. In contrast, studies of patients
with FL treated with cyclophosphamide, doxorubicin,
vincristine, prednisone (CHOP), and rituximab did
not find that FcRIIIA or RIIA polymorphisms corre-
lated with outcome [34,35].
The impact of immune response SNPs in FL was
analyzed resulting in identification of a final set of
four prognostically relevant immune response SNPs
(IL-8, IL-2, IL-12B, and IL-1RN [30]). An outcome
predictor was built using clinical and demographic fac-
tors combined with the four deleterious SNPs, which
identified three risk groups with 5-year OS estimates
of 96%, 72%, and 58%, respectively. These patients
were treated in an era before the use of rituximab. Al-
though these four genes strongly predicted outcome in
patients with FL, none was associated with the risk of
developing FL [30,36]. These results suggest that the
composition and functional status of the immune
cells in the tumor microenvironment of FL may be
driven by the genetics of the host.
Improved biologic insight into the pathogenesis of
FL highlights the complex interaction between the
malignant tumor cell, nonmalignant cells of themicro-
environment, and host genetic factors that ultimately
help determine outcome. Althoughmany biologic cor-
relates have been linked to prognosis, inconsistencies
in the literature and lack of validation currently limit
the value of molecular prognostic indicators. Further-
more, the impact of molecular factors may vary de-
pending on the treatment received and thus should
be evaluated in the context of specific therapeutic ap-
proaches. The FLIPI and FLIPI-2 are useful clinical
tools but do not provide biologic insight or identify pa-
tients with sufficiently poor outcomes to warrant alter-
native therapy and, thus, are of limited value in guiding
the choice of initial treatment.
Treatment for FL
Conventional therapy
Although FL can undergo histologic transforma-
tion, the disease usually follows an indolent clinical
course. Because most patients have advanced-stage
disease, this section focuses on the treatment of
advanced-stage, low-grade (grade 1-2) FL.
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is whether immediate treatment is required. A
‘‘watch-and-wait’’ approach is appropriate in asymp-
tomatic patients with low disease burden, such as those
with no site of disease of $7 cm and no more than
three sites of disease between 3 to 7 cm. In addition
to disease burden, other indications for treatment in-
clude symptomatic extranodal disease, ‘‘B’’ symptoms,
massive or symptomatic splenomegaly, cytopenias
from extensive bone marrow involvement, or threat-
ened end-organ function. Patients who do not require
immediate treatment should be assessed periodically
to determine whether treatment is indicated. In addi-
tion, a steady progression of disease over 6 months is
also an indication for treatment [37].
When treatment is indicated, options include single-
agent rituximab or a rituximab-chemotherapy combina-
tion. For patients with a low disease burden, or who are
elderly or frail, single-agent rituximab may be effective,
with more than 50% of patients responding [38,39].
Other frontline options for frail or low-disease-burden
patients include chlorambucil (with or without
rituximab) or radioimmunotherapy (RIT). An
American intergroup trial randomized 554 newly
diagnosed patients with FL to either rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone
(R-CHOP) vs CHOP plus iodine-131 tositumumab
[40]. With a median follow-up of 5 years, there was no
difference between the two arms in terms of OS, PFS,
or serious adverse events.
For patients with high disease burden or severe
symptoms, a rituximab/chemotherapy combination is
generally used. In several studies, the addition of ritux-
imab to various chemotherapy regimens improves PFS
and evenOS in some studies [41-43]. Between 2004 and
2007, in the United States, R-CHOP was the most
commonly used initial regimen in patients with FL
[44]. Rituximab, cyclophosphamide, vincristine, and
prednisone (R-CVP) are also frequently used. Com-
pared to R-CHOP, R-CVP is somewhat less active,
but also less toxic [43]. More recently, bendamustine
plus rituximab has become a popular frontline regimen
based on preliminary data showing improved efficacy
and reduced toxicity vs R-CHOP [45].
After first-line chemoimmunotherapy, patients may
undergo observation, ‘‘maintenance’’ rituximab, or con-
solidation with RIT. The Primary Rituximab andMain-
tenance (PRIMA) phase 3 randomized trial studied the
impact of maintenance rituximab after frontline rituxi-
mab/chemotherapy treatment [46]. An improved
3-year PFS was reported in favor of rituximab mainte-
nance, although no difference in OS was seen. Other
studies in the frontlinesettinghavesimilarly shownaben-
efit to maintenance rituximab after induction therapy
with rituximab or CVP [47,48]. 98Y-ibritumomab
tiuxetan has been studied as consolidation after
frontline chemotherapy (1/2 rituximab). Patientsreceiving RIT consolidation have improved PFS
compared to those observed after frontline therapy.
However, interpretation of these data is limited
because the majority of patients did not receive
rituximab with induction [49].
There are many potential treatment options to
consider for recurrent FL. When possible, patients
should be enrolled on a clinical trial. Off-protocol op-
tions include (1) single-agent rituximab with or with-
out maintenance rituximab, (2) various chemotherapy
regimens (1/2 rituximab) including bendamustine,
CHOP, chlorambucil, fludarabine, or platinum-
based regimens, (3) RIT, or (4) external-beam radia-
tion therapy [37]. In general, for patients previously
exposed to (or resistant to) rituximab, these approaches
are associated with a median PFS in the 6- to 18-
month range. Such treatments may also be used as
cytoreductive strategies before HCT. In selecting
treatment, one needs to consider which therapies
have been previously administered, prior response,
number of relapses, and patient factors such as age, co-
morbidities, and the patient’s goals of therapy. For
example, with an early relapse (\12 months), a non-
cross-resistant regimen is suggested (eg, bendamustine
if R-CHOPwas used previously). Additionally, adding
rituximab may be beneficial if the patient previously
had a response to a rituximab-containing regimen
that lasted at least 6 months.
Novel Agents
Awide variety of commercially available novel agents
show promise in FL. These include the proteosome in-
hibitor, bortezomib, the fully humanized anti-CD20
antibody, ofatumumab, the mammalian target of rapa-
mycin (mTOR) inhibitors, everolimus and temsirolimus,
and the histone deacetylase inhibitor, vorinostat.
Bortezomib, a selective inhibitor of the 26S protea-
some, has been studied in both the relapsed/refractory
and frontline treatment of FL. In a large randomized
phase 3 trial of relapsed rituximab-na€ıve or rituximab-
sensitive FL, single-agent rituximab was compared to
the combination of bortezomib and rituximab. The
bortezomib plus rituximab arm had a median PFS of
12.8 months vs 11.0 months in the rituximab alone
arm [50]. The combination of bendamustine, bortezo-
mib, and rituximab showed an 88% overall response
rate (including 53% complete response) in 63 patients
with relapsed/refractory FL. PFS was 14.9 months
[51]. Due to the high activity of this regimen, benda-
mustine, bortezomib, and rituximab are now being
tested in the frontline setting as one arm of the ongoing
Eastern Cooperative Oncology Group 2408 protocol.
Adding bortezomib to R-CVP is also feasible and well
tolerated with a complete response rate comparing fa-
vorably to historical controls [52].
The immunomodulatory agent, lenalidomide, was
tested as a single agent in relapsed or refractory
S86 Biol Blood Marrow Transplant 18:S82-S91, 2012L. H. Sehn et al.indolent NHL, with a 27% overall response rate in
patients with FL. Median duration of response was
longer than 16.5 months [53].
A large number of monoclonal antibodies are un-
dergoing evaluation for B cell NHL, including FL.
These novel antibodies target distinct CD20 epitopes,
or non-CD20 surface markers. These agents may offer
therapeutic advantages such as higher potency for
antibody-dependent or complement-mediated cyto-
toxicity and may overcome rituximab resistance or
lead to additive/synergistic effects when combined
with other therapeutic agents. Ofatumumab is a fully
humanized monoclonal antibody that targets a distinct
epitope on the CD20 molecule. In relapsed/refractory
FL, an overall response rate of 42%was seen,with ame-
dian duration of response 29.9 months [54]. However,
in a separate study of ofatumumab in rituximab-
refractory patients, a response rate of only 11% was
seen [55]. Inpreviously untreatedpatients, ofatumumab
was combined with CHOP chemotherapy with com-
plete responses seen in 69% and an overall response
rate up to 100%, with favorable toxicity profiles [56].
The PI3K/Akt/mTOR signaling pathway is acti-
vated in many lymphoid malignancies and is therefore
an attractive target for therapy. Everolimus and tem-
sirolimus are first-generation mTOR inhibitors that
are Food & Drug Administration-approved for the
treatment of renal cell carcinoma. Everolimus as a sin-
gle agent produced a 50% response rate in 16 patients
with FL [57]. Temsirolimus also shows promising
activity in patients with relapsed FL, with an overall re-
sponse rate of 35% [58].
The histone deacetylase inhibitor, vorinostat, has
been evaluated in patients with relapsed/refractory in-
dolent lymphoma. Of the 17 patients with FL, a 47%
overall response rate was reported, with a median
PFS of 15.6 months [59].
In addition to the current commercially available
agents discussed previously, a large number of other
novel agents are under development. These include
novel monoclonal antibodies, antibody/toxin conju-
gates, as well as agents which target B cell receptor sig-
naling (fostamatinib, PCI-32765), protein kinase C
(enzastaurin), PI3K (CAL-101), the proteosome,
HDACs, and others [60].HCT
For patients with FL with advanced disease, HCT
has been used as an alternative approach, especially to
younger patients but typically was offered late in their
course because of the long natural history inherent to
this disease and the nonrelapsemortality (NRM) associ-
ated withHCT.However, refinements in HCT includ-
ing improved donor selection, better supportive care,
and allogeneic reduced-intensity conditioning regimens
have lowered NRM and thus broadened eligibility.Autologous HCT
Several trials have unequivocally reported im-
proved disease-free survival (DFS) with one random-
ized trial showing an OS benefit in patients with
chemosensitive relapsed FL [61,62]. The European
Blood and Marrow Transplant (EBMT) conducted
the CUP trial (chemotherapy vs unpurged arm vs
purged arm) that prospectively addressed the role of
autologous HCT in 140 patients with relapsed
FL [63]. There was a significant reduction in hazard
rates for both PFS and OS when comparing the
chemotherapy- only patients and the combined groups
of patients with autologous HCT. The 4-year OS was
46% for the chemotherapy arm, 71% for the unpurged
arms, and 77% for the HCT purged arms. The sample
sizes in the two HCT arms were too small to measure
the effect of ex vivo purging. Unfortunately, this trial
closed early due to slow accrual and was also conduct-
ed in the pre-rituximab era, which limits the relevance
of the previously mentioned findings. The Groupe
d’Etude des Lymphomes de l’Adulte/Group Ouest-
Est des Leucemies et des Autres Maladies du Sang
(GELA/GOELAMS) groups retrospectively exam-
ined the impact of autologous HCT in patients with
FL at first relapse [64]. In this series of 175 patients,
the 3-year OS was significantly higher in patients
who proceeded to HCT vs patients who did not
undergo HCT (92% vs 63%; P 5 .0003). This study
included patients who received prior rituximab. How-
ever, as this was a retrospective study, the favorable im-
pact of HCT may have been affected by selection bias
because only patients responding to salvage therapy
proceeded to HCT. The addition of radioimmuno-
conjugates to high-dose chemotherapy has also been
explored in this setting [65,66].
Autologous HCT as consolidation in first com-
plete remission has not shown anOS benefit compared
to conventional chemotherapy alone based on four
large randomized European trials and thus cannot be
recommended as part of frontline therapy [67-70].
Three of the four trials showed a higher event-free sur-
vival (EFS) or PFS in theHCT arms compared to con-
ventional chemotherapy, but there was no advantage in
OS in all four trials. Additionally, the cumulative inci-
dence of secondary malignancies was notably higher in
the HCT arms in three of the trials.Myeloablative Allogeneic HCT
Allogeneic HCT (alloHCT) is the only treatment
modality with curative potential for patients with ad-
vanced FL. In contrast to autologous HCT, alloHCT
uses the graft-vs-lymphoma (GVL) effect mediated by
donor T cells to eradicate minimal residual disease and
circumvents potential tumor cell contamination in the
graft. Despite the lower relapse risk associated with
myeloablative alloHCT, this benefit has been offset
Table 2. Prospective Trials of Reduced-Intensity Allogeneic HCT for Relapsed Follicular Lymphoma
No. of Patients
Median Age
(range)
% Prior
AutoHCT
Preparation
Regimen Donor Type DFS/EFS OS TRM Median Follow-up
CALGB [85]
2011
44 (16 with FL) 53 (39-68) 0 Flu/Cy MRD 75% 81% 9% 4.6 yr
United Kingdom [77]
2010
82 45 (26-65) 26 Flu/Mel/Alem MRD
URD
76% 76% 15% 43 mo
GELTAMO [81]
2010
37 50 (34-62) 46 Flu/Mel MRD 57% 54% 37% 52 mo
FHCRC [84]
2008
62 (54 with FL) 54 (33-66) 32 TBI +/2 Flu MRD
URD
43% 52% 42% 36 mo
MD Anderson [80]
2008
47 53 (33-68) 19 Flu/Cy/RTX MRD
URD
83% 85% 15% 60 mo
HCT indicates hematopoietic cell transplantation; autoHCT, autologous hematopoietic cell transplantation; DFS/EFS, disease-free survival/event-free
survival; OS, overall survival; TRM, treatment-related mortality; CALGB, Cancer and Leukemia Group B; FL, follicular lymphoma; Flu, fludarabine;
Cy, cyclophosphamide; MRD, matched related donor; Mel, melphalan; Alem, alemtuzumab; URD, unrelated donor; GELTAMO, Grupo Espa~nol de Lin-
fomas/Trasplante Autologo de Medula Osea; FHCRC, Fred Hutchinson Cancer Research Center; TBI, total body irradiation; RTX, rituximab.
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regimen. An analysis from the Center for International
Blood and Marrow Transplant Research (CIBMTR)
compared the outcomes of 904 patients with FL who
underwent myeloablative alloHCT, purged autolo-
gous HCT, or unpurged autologous HCT [71]. There
was a 54% lower risk of relapse in the allogeneic group
(P \ .001) and a 26% reduction in relapse in the
purged autograft group compared to the recipients of
unpurged grafts. After 1 year, a plateau in relapse
risk was observed in the allogeneic recipients as
opposed to a continuous pattern of treatment failure
in the autologous group. The EBMT reported the out-
comes of 1,185 patients with NHL including 231 pa-
tients with low-grade NHL who underwent
myeloablative alloHCT and compared the results
with 14,687 autologous HCT recipients [72]. Al-
though relapse risk was significantly lower among
the allogeneic recipients, OS was comparable between
the autologous and allogeneic recipients due to the
prohibitive 4-year treatment-related mortality
(TRM) of 38%. Three single-institution retrospective
analyses have shown long-term DFS in patients with
FL including patients with chemoresistant disease af-
ter myeloablative allogeneic HCT. The 5-year EFS
from these three series ranged from 45% to 75%,
and outcomes varied depending on chemosensitivity
at the time of HCT [73-75].
Allogeneic Reduced-Intensity HCT
Reduced-intensity conditioning (RIC) incorpo-
rates a less intensive preparative regimen and relies
more on the immunotherapeutic effects of the allograft
to confer antitumor activity rather than the cytoreduc-
tion of high-dose chemotherapy. The goal of RIC is to
adequately immunosuppress the recipient to allow en-
graftment of donor cells with a minimal to moderate
amount of cytoreduction. RIC regimens are being in-
creasingly used, and results have been highly encour-
aging. Such regimens are associated with a lower risk
of NRM and can be offered to older patients in con-trast to ablative regimens. Among the various NHL
histologies, the GVL effect seems to be the most po-
tent against the indolent histologies, especially in pa-
tients with FL [76].
Table 2 provides details on five selected prospec-
tive trials of patients with FL undergoing RIC al-
loHCT with four of the five trials including patients
who had failed a prior autologous HCT. The largest
prospective series originates from the United King-
dom in which 82 patients with FL (21 patients had
failed a prior autologous HCT) underwent a condi-
tioning regimen of fludarabine, melphalan, and alem-
tuzumab [77]. The alemtuzumab was administered
for the main purpose of in vivo T cell depletion
(TCD). Grade 2 to 3 acute graft-versus-host disease
(GVHD) was seen in only 13% of patients, and the
4-year cumulative incidence of extensive chronic
GVHD was 18%. The 4-year PFS was 76% for all pa-
tients, but when analyzed by donor type, the PFS in-
creased to 90% for recipients of matched sibling
donors and was 64% for recipients of unrelated donor
grafts. Relapse risk was 26% and was significantly
higher in patients with persistently mixed donor chi-
merism vs patients who achieved full donor chimerism
(relapse incidence: 40% vs 14%, respectively; P5 .01).
Additionally, 13 patients who relapsed received donor
lymphocyte infusion with nine patients experiencing
a sustained remission, which lends further support to
the GVL effect against FL.
A retrospective series from theEBMTgroup aimed
to assess the impact of in vivo TCD in patients with ad-
vanced FL undergoing RIC alloHCT from matched
sibling donors [78]. For analytical purposes, patients
were divided into groups who received anti-
thymocyte globulin (n 5 46), patients who received
alemtuzumab (n5 42), and patients who received nei-
ther agent in the preparative regimen (n 5 76). The
incidences of acute and chronic GVHD were signifi-
cantly lower in the in vivo TCD group compared
with patients not receiving a TCD agent (acute, 17%
vs 31%, respectively; P 5 .04; and chronic 33% vs
S88 Biol Blood Marrow Transplant 18:S82-S91, 2012L. H. Sehn et al.73%, respectively; P \ .01). However, the use of
a TCD agent did not affect NRM despite the lower in-
cidence ofGVHD.Disease status atHCTwas the only
factor that emerged as a true predictor of outcome.The
French Society of BoneMarrowGraftTransplantation
and Cellular Therapy retrospectively reported the out-
comes of 73 patients with FL after RIC alloHCT [79].
The 3-year OS and EFS were 56% and 51%, respec-
tively, with a relapse rate of 9.6%. As with the EBMT
series, chemosensitivity was predictive of OS and EFS.
Some of the most encouraging data originated from
the MD Anderson Group in which 47 patients (n5 45
matched related donor; n 5 2 unrelated donor) with
relapsed FL underwent alloHCT using the fludarabine,
cyclophosphamide, rituximab conditioning regimen
[80]. The complete remission rate after alloHCT was
100%. With a median follow-up of 60 months, the OS
and PFS were 85% and 83%, respectively. The inci-
dence of grade 2 to 4 acute GVHD was only 11% with
a 36% incidence of extensive chronic GVHD. One dis-
tinctive feature of this studywas the use of high-dose rit-
uximab in which three of the four planned doses of
rituximab were given at 1,000 mg/m2. In contrast to
the previously mentioned study from the United King-
dom, thedepthofdonor chimerismdidnot affect relapse
risk. In light of these impressive results, the Blood and
Marrow Transplant Clinical Trials Network (BMT
CTN) has embarked on a phase II multicenter trial for
relapsed patients with FL with the goal to validate the
highly promising results using the fludarabine, cyclo-
phosphamide, rituximab regimen in the setting of RIC
alloHCT. The Grupo de Espanol de Linfomas/Trans-
plante Autologo de Medula Osea (GELTAMO) group
reported the results of 37 patients with matched sibling
donors who received fludarabine and melphalan as the
conditioning regimen [81]. The 4-year DFS was 55%
with a relapse rate of 8%, which is notable considering
that 46%of patients had failed a prior autologousHCT.
The CIBMTRperformed retrospective analyses to
compare outcomes of patients with FL who received
a myeloablative regimen (n 5 120) vs an RIC regimen
(n5 88) [82].The type of conditioning regimen did not
have an impact on PFS, OS, and TRM but did affect
progression. Inmultivariate analysis, therewas a signif-
icantly higher risk of progression with RIC alloHCT
(RR,2.97; 95% confidence interval, 1.03-8.55; P 5
.044). The 3-year progression rate was 8% in the abla-
tive group vs 17% in the RIC group. It should be noted
that the RIC recipients were older than the ablative re-
cipients (median age, 51 years vs 44 years, respectively),
had a longer time from diagnosis to HCT (36 vs 25
months, respectively), and a higher incidence of co-
morbid conditions. Chemosensitivity and recipient
performance status were better predictors of outcome
rather than conditioning regimen used. There are no
prospective randomized trials comparing outcomes
between autologous HCT vs RIC alloHCT for pa-tients with relapsed FL. The Blood and Marrow
Transplant Clinical Trials Network embarked on
a biological assignment trial to address this question,
but the trial closed prematurely due to poor accrual
[83]. A total of 30 patients were accrued with eight pa-
tients in the alloHCT arm and 22 patients proceeding
to autologous HCT. With a median follow-up of
36 months, the OS was 73% vs 100%, and the PFS
was 63% vs 86% in the autologous and RIC alloHCT
arms, respectively, with TRM at 1 year being 15% and
0%, respectively. Due to the small sample sizes, statis-
tical comparisons were not possible.
In summary, both autologous and alloHCT can
confer long-term survival in patients with relapsed
FL. HCT should be offered to patients who have pro-
gressed after one to two prior regimens if they have
a good performance status and can tolerate an aggres-
sive approach. For patients who are not heavily pre-
treated and who are chemosensitive at the time of
relapse, autologous HCT is a reasonable approach.
However, numerous allogeneic HCT trials have
shown the existence of robust graft-vs-lymphoma ef-
fect in FL, and prolonged DFS has been shown in sev-
eral studies. The NRM associated with myeloablative
regimens remains prohibitive, and thus RIC allogeneic
HCT has become the de facto standard in alloHCT
for patients with FL. The CIBMTR reported that
the number of RIC regimens increased from\10%
of transplantations in 1997 to .80% in 2002 [82].
Risk factors for relapse after RIC regimens include
chemorefractory disease and transformed disease,
and thus chemosensitivity should be established before
alloHCT [84]. The optimal choice between proceed-
ing to autologousHCT or RIC alloHCT for a chemo-
sensitive relapsed patient with FL is not definitive, but
the advent of RIC allogeneic HCT and associated
promising results has led to a major shift in practice
in increased utilization of RIC regimens.CONCLUSION
The definitive management of patients with
advanced follicular NHL remains under considerable
debate due to the numerous treatment options available.
Fortunately, response rates are increasing, and recent re-
sults show that OS seems to be improving. The goal of
treatment is to alleviate symptoms of the disease and
to emphasize quality of life. HCT should be offered.
Thegreater availabilityof treatment options further em-
phasizes the utility of predictive biomarkers and prog-
nostic indices to guide risk-adapted therapies with the
ultimate goals of increasing survival with less toxicities.ACKNOWLEDGMENTS
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